{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T15:04:38Z","timestamp":1786115078146,"version":"build-2736575974"},"reference-count":69,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100006506","name":"Minist\u00e9rio da Sa\u00fade","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006506","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["celltherapyjournal.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cytotherapy"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.jcyt.2026.102780","type":"journal-article","created":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T17:30:26Z","timestamp":1773250226000},"page":"102780","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Overcoming challenges in the implementation of chimeric antigen receptor (CAR) T-cell therapy in resource-constrained settings: Lessons from Brazil and India"],"prefix":"10.1016","volume":"28","author":[{"given":"Flavia","family":"Gava","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7010-9648","authenticated-orcid":false,"given":"Alka","family":"Dwivedi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9947-7065","authenticated-orcid":false,"given":"Hasmukh","family":"Jain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kirk R.","family":"Schultz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7514-096X","authenticated-orcid":false,"given":"Diego V.","family":"Cl\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8474-9080","authenticated-orcid":false,"given":"Nirali N.","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"16","key":"10.1016\/j.jcyt.2026.102780_bib0001","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1056\/NEJMoa1407222","article-title":"Chimeric antigen receptor T cells for sustained remissions in leukemia","volume":"371","author":"Maude","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jcyt.2026.102780_bib0002","doi-asserted-by":"crossref","DOI":"10.1016\/j.blre.2023.101136","article-title":"Access to CAR T-cell therapy: focus on diversity, equity and inclusion","volume":"63","author":"Odstrcil","year":"2024","journal-title":"Blood Rev"},{"issue":"2","key":"10.1016\/j.jcyt.2026.102780_bib0003","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1002\/cpt.3703","article-title":"FDA experience on CAR T cell pharmacokinetics\/pharmacodynamics and model-based assessments","volume":"118","author":"Tegenge","year":"2025","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.jcyt.2026.102780_bib0004","unstructured":"US Food and Drug Administration. Approved cellular and gene therapy products. Available from: https:\/\/www.fda.gov\/vaccines-blood-biologics\/cellular-gene-therapy-products\/approved-cellular-and-gene-therapy-products."},{"key":"10.1016\/j.jcyt.2026.102780_bib0005","unstructured":"European Medicines Agency. CAT quarterly highlights and approved ATMPs. 2025. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/committee-report\/cat-quarterly-highlights-approved-atmps-may-2025_en.pdf."},{"issue":"12","key":"10.1016\/j.jcyt.2026.102780_bib0006","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1200\/OP.22.00315","article-title":"Chimeric antigen receptor T-cell therapies: barriers and solutions to access","volume":"18","author":"Mikhael","year":"2022","journal-title":"JCO Oncol Pract"},{"issue":"12","key":"10.1016\/j.jcyt.2026.102780_bib0007","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-009611","article-title":"CAR-T cell therapy in developing countries: how long should we wait?","volume":"12","author":"Gautam","year":"2024","journal-title":"J Immunother Cancer"},{"issue":"746","key":"10.1016\/j.jcyt.2026.102780_bib0008","doi-asserted-by":"crossref","first-page":"eadn1902","DOI":"10.1126\/scitranslmed.adn1902","article-title":"The translational gap for gene therapies in low- and middle-income countries","volume":"16","author":"Doxzen","year":"2024","journal-title":"Sci Transl Med"},{"issue":"16","key":"10.1016\/j.jcyt.2026.102780_bib0009","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1002\/cncr.28748","article-title":"Declining childhood and adolescent cancer mortality","volume":"120","author":"Smith","year":"2014","journal-title":"Cancer"},{"issue":"6","key":"10.1016\/j.jcyt.2026.102780_bib0010","doi-asserted-by":"crossref","first-page":"e223","DOI":"10.1016\/S1470-2045(14)70117-2","article-title":"Delivery of affordable and equitable cancer care in India","volume":"15","author":"Pramesh","year":"2014","journal-title":"Lancet Oncol"},{"issue":"6","key":"10.1016\/j.jcyt.2026.102780_bib0011","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1097\/CCO.0000000000000125","article-title":"Acute lymphoblastic leukemia in low and middle-income countries: disease characteristics and treatment results","volume":"26","author":"Abboud","year":"2014","journal-title":"Curr Opin Oncol"},{"key":"10.1016\/j.jcyt.2026.102780_bib0012","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.922370","article-title":"Editorial: Real world outcomes of lymphoma from India","volume":"12","author":"Kumar","year":"2022","journal-title":"Front Oncol"},{"issue":"6","key":"10.1016\/j.jcyt.2026.102780_bib0013","doi-asserted-by":"crossref","first-page":"2122","DOI":"10.1016\/j.ymthe.2022.04.002","article-title":"Gene therapy access: global challenges, opportunities, and views from Brazil, South Africa, and India","volume":"30","author":"Cornetta","year":"2022","journal-title":"Mol Ther"},{"issue":"Pt B","key":"10.1016\/j.jcyt.2026.102780_bib0014","article-title":"Childhood cancer in India","volume":"71","author":"Ganguly","year":"2021","journal-title":"Cancer Epidemiol"},{"issue":"4","key":"10.1016\/j.jcyt.2026.102780_bib0015","doi-asserted-by":"crossref","first-page":"299","DOI":"10.4103\/0971-5851.125250","article-title":"Histopathological pattern of lymphomas and clinical presentation and outcomes of diffuse large B cell lymphoma: a multicenter registry based study from India","volume":"34","author":"Nimmagadda","year":"2013","journal-title":"Indian J Med Paediatr Oncol"},{"issue":"2","key":"10.1016\/j.jcyt.2026.102780_bib0016","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1002\/pbc.21897","article-title":"Survival outcome in childhood ALL: experience from a tertiary care centre in North India","volume":"53","author":"Kulkarni","year":"2009","journal-title":"Pediatr Blood Cancer"},{"issue":"6","key":"10.1016\/j.jcyt.2026.102780_bib0017","doi-asserted-by":"crossref","first-page":"e255","DOI":"10.1016\/j.clml.2018.03.001","article-title":"Treating adult acute lymphoblastic leukemia in Brazil\u2014increased early mortality using a German multicenter acute lymphoblastic leukemia-based regimen","volume":"18","author":"Fernandes da Silva Junior","year":"2018","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"Suppl. 2","key":"10.1016\/j.jcyt.2026.102780_bib0018","first-page":"S142","article-title":"Treatment results of three consecutive Brazilian cooperative childhood ALL protocols: GBTLI-80, GBTLI-82 and -85. ALL Brazilian Group","volume":"7","author":"Brandalise","year":"1993","journal-title":"Leukemia"},{"key":"10.1016\/j.jcyt.2026.102780_bib0019","unstructured":"ClinicalTrials.gov. May 2025. Available from: https:\/\/clinicaltrials.gov\/search?term=Chimeric%20Antigen%20Receptor%20&viewType=Card."},{"issue":"3","key":"10.1016\/j.jcyt.2026.102780_bib0020","first-page":"163","article-title":"Barriers to chimeric antigen receptor T-cell (CAR-T) therapies in clinical practice","volume":"36","author":"Gajra","year":"2022","journal-title":"Pharmaceut Med"},{"key":"10.1016\/j.jcyt.2026.102780_bib0021","unstructured":"The World Bank, World Bank Country and Lending Groups. Available from:https:\/\/datahelpdesk.worldbank.org\/knowledgebase\/articles\/906519-world-bank-country-and-lending-groups."},{"issue":"11","key":"10.1016\/j.jcyt.2026.102780_bib0022","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1016\/j.jcyt.2025.07.007","article-title":"Overcoming barriers to referral for CAR T-cell therapy in patients with non-Hodgkin aggressive B-cell lymphomas: a Delphi consensus","volume":"27","author":"Luminari","year":"2025","journal-title":"Cytotherapy"},{"issue":"4","key":"10.1016\/j.jcyt.2026.102780_bib0023","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.jtct.2023.03.003","article-title":"Ethical challenges in CAR-T slot allocation","volume":"29","author":"Faiman","year":"2023","journal-title":"Transplant Cell Ther"},{"issue":"2","key":"10.1016\/j.jcyt.2026.102780_bib0024","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.jcyt.2021.09.007","article-title":"CAR-T cell therapy in India requires a paradigm shift in training, education and health care processes","volume":"24","author":"Ravindranath","year":"2022","journal-title":"Cytotherapy"},{"key":"10.1016\/j.jcyt.2026.102780_bib0025","article-title":"Childhood leukemias in Mexico: towards implementing CAR-T cell therapy programs","volume":"13","author":"Bustamante-Ogando","year":"2023","journal-title":"Front Oncol"},{"issue":"Suppl. 2","key":"10.1016\/j.jcyt.2026.102780_bib0026","doi-asserted-by":"crossref","first-page":"S68","DOI":"10.1016\/j.htct.2021.09.010","article-title":"Associacao Brasileira de Hematologia, Hemoterapia e Terapia Celular Consensus on genetically modified cells. Special Article: Advanced therapy medicinal products in Brazil: regulatory panorama","volume":"43","author":"Silva Junior","year":"2021","journal-title":"Hematol Transfus Cell Ther"},{"issue":"5","key":"10.1016\/j.jcyt.2026.102780_bib0027","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/j.jcyt.2021.10.008","article-title":"Comparison of new Brazilian legislation for the approval of advanced therapy medicinal products with existing systems in the USA, European Union and Japan","volume":"24","author":"Gomes","year":"2022","journal-title":"Cytotherapy"},{"issue":"7","key":"10.1016\/j.jcyt.2026.102780_bib0028","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1016\/j.jcyt.2019.04.002","article-title":"Current state of U.S. Food and Drug Administration regulation for cellular and gene therapy products: potential cures on the horizon","volume":"21","author":"Mendicino","year":"2019","journal-title":"Cytotherapy"},{"key":"10.1016\/j.jcyt.2026.102780_bib0029","unstructured":"US Food & Drug Administration (FDA). Considerations for the development of chimeric antigen receptor (CAR) t cell products. [cited 2025]. Available from:https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/considerations-development-chimeric-antigen-receptor-car-t-cell-products."},{"issue":"6","key":"10.1016\/j.jcyt.2026.102780_bib0030","doi-asserted-by":"crossref","first-page":"S186","DOI":"10.1016\/j.jcyt.2024.03.369","article-title":"Regulatory framework for developing cell & gene therapy products in India","volume":"26","author":"Pandit","year":"2024","journal-title":"Cytotherapy"},{"key":"10.1016\/j.jcyt.2026.102780_bib0031","doi-asserted-by":"crossref","DOI":"10.1038\/mto.2016.15","article-title":"Clinical manufacturing of CAR T cells: foundation of a promising therapy","volume":"3","author":"Wang","year":"2016","journal-title":"Mol Ther Oncolytics"},{"issue":"5","key":"10.1016\/j.jcyt.2026.102780_bib0032","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1038\/s41587-025-02691-z","article-title":"Brazil's low-cost CAR-Ts take on Global South","volume":"43","year":"2025","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.jcyt.2026.102780_bib0033","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1200\/EDBK_155975","article-title":"Access to cancer therapeutics in low- and middle-income countries","volume":"35","author":"Ruff","year":"2016","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"10.1016\/j.jcyt.2026.102780_bib0034","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2024.1397613","article-title":"Obstacles to global implementation of CAR T cell therapy in myeloma and lymphoma","volume":"14","author":"Medina-Olivares","year":"2024","journal-title":"Front Oncol"},{"key":"10.1016\/j.jcyt.2026.102780_bib0035","doi-asserted-by":"crossref","DOI":"10.2217\/imt-2022-0037","article-title":"Barriers and solutions to improve access for chimeric antigen receptor therapies","author":"Kamal-Bahl","year":"2022","journal-title":"Immunotherapy"},{"issue":"6","key":"10.1016\/j.jcyt.2026.102780_bib0036","doi-asserted-by":"crossref","first-page":"356.e1","DOI":"10.1016\/j.jtct.2023.03.022","article-title":"Access to chimeric antigen receptor T cell clinical trials in underrepresented populations: a multicenter cohort study of pediatric and young adult acute lymphoblastic leukemia patients","volume":"29","author":"Hall","year":"2023","journal-title":"Transplant Cell Ther"},{"issue":"4","key":"10.1016\/j.jcyt.2026.102780_bib0037","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1016\/S1470-2045(20)30145-5","article-title":"Treating childhood cancer: a necessity not a choice","volume":"21","author":"Landman","year":"2020","journal-title":"Lancet Oncol"},{"issue":"4","key":"10.1016\/j.jcyt.2026.102780_bib0038","doi-asserted-by":"crossref","first-page":"e185","DOI":"10.1016\/S1470-2045(20)30022-X","article-title":"Sustainable care for children with cancer: a Lancet Oncology Commission","volume":"21","author":"Atun","year":"2020","journal-title":"Lancet Oncol"},{"issue":"2","key":"10.1016\/j.jcyt.2026.102780_bib0039","doi-asserted-by":"crossref","DOI":"10.1016\/j.transci.2023.103679","article-title":"Apheresis in pediatric patients: current differences and difficulties","volume":"62","author":"Aksoy","year":"2023","journal-title":"Transfus Apher Sci"},{"issue":"3","key":"10.1016\/j.jcyt.2026.102780_bib0040","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1111\/bcp.12305","article-title":"Clinical trials in children","volume":"79","author":"Joseph","year":"2015","journal-title":"Br J Clin Pharmacol"},{"issue":"2","key":"10.1016\/j.jcyt.2026.102780_bib0041","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1111\/bjh.19170","article-title":"The academic point-of-care anti-CD19 chimeric antigen receptor T-cell product varnimcabtagene autoleucel (ARI-0001 cells) shows efficacy and safety in the treatment of relapsed\/refractory B-cell non-Hodgkin lymphoma","volume":"204","author":"Martinez-Cibrian","year":"2024","journal-title":"Br J Haematol"},{"issue":"3","key":"10.1016\/j.jcyt.2026.102780_bib0042","doi-asserted-by":"crossref","first-page":"206","DOI":"10.4274\/tjh.galenos.2022.2022.0193","article-title":"Preliminary report of the academic CAR-T (ISIKOK-19) cell clinical trial in Turkey: characterization of product and outcomes of clinical application","volume":"39","author":"Erdogan","year":"2022","journal-title":"Turk J Haematol"},{"key":"10.1016\/j.jcyt.2026.102780_bib0043","unstructured":"India - Global Cancer Observatory. Available from: https:\/\/gco.iarc.who.int\/media\/globocan\/factsheets\/populations\/356-india-fact-sheet.pdf."},{"key":"10.1016\/j.jcyt.2026.102780_bib0044","unstructured":"World Bank Group - GDP per capita (current US$) - India. Available from: https:\/\/data.worldbank.org\/indicator\/NY.GDP.PCAP.CD?locations=IN."},{"key":"10.1016\/j.jcyt.2026.102780_bib0045","unstructured":"World Bank Group - Current health expenditure per capita (current US$) - Brazil, India [January 23, 2026]. Available from:https:\/\/data.worldbank.org\/indicator\/SH.XPD.CHEX.PC.CD?locations=BR-IN."},{"issue":"5","key":"10.1016\/j.jcyt.2026.102780_bib69","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1158\/1535-7163.MCT-20-0476","article-title":"Robust Antitumor activity and low cytokine production by novel humanized anti-CD19 CAR T cells","volume":"20","author":"Dwivedi","year":"2021","journal-title":"Mol Cancer Ther"},{"issue":"4","key":"10.1016\/j.jcyt.2026.102780_bib0046","doi-asserted-by":"crossref","first-page":"e282","DOI":"10.1016\/S2352-3026(24)00377-6","article-title":"Talicabtagene autoleucel for relapsed or refractory B-cell malignancies: results from an open-label, multicentre, phase 1\/2 study","volume":"12","author":"Jain","year":"2025","journal-title":"Lancet Haematol"},{"issue":"Suppl. 1","key":"10.1016\/j.jcyt.2026.102780_bib0047","article-title":"Real world data of novel talicabtagene Autoleucel (humanized CD19 CAR-T) from India; ensuring equitable access with excellent safety and efficacy profile","volume":"144","author":"Jain","year":"2024","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.jcyt.2026.102780_bib0048","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1038\/s41408-025-01279-9","article-title":"Novel humanized CD19-CAR-T (now talicabtagene autoleucel, Tali-cel) cells in relapsed\/refractory pediatric B-acute lymphoblastic leukemia\u2014an open-label single-arm phase-I\/Ib study","volume":"15","author":"Narula","year":"2025","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.jcyt.2026.102780_bib0049","unstructured":"Immuneel Therapeutics, Hospital Cl\u00ednic de Barcelona & IDIBAPS Announce a Strategic collaboration & a License Agreement. October 13, 2020. Available from:https:\/\/www.clinicbarcelona.org\/en\/news\/immuneel-therapeutics-hospital-clinic-de-barcelona-idibaps-announce-a-strategic-collaboration-a-license-agreement."},{"key":"10.1016\/j.jcyt.2026.102780_bib0050","unstructured":"Brazilian Health Regulatory Agency :Anvisa). Approval letter \u2013 Kymriah. 2022 [cited 2025]. Available from: https:\/\/www.gov.br\/anvisa\/pt-br\/assuntos\/sangue\/terapias-avancadas\/ensaios-clinicos-autorizados\/cartas-de-aprovacao\/carta-de-aprovacao-kymriah.pdf."},{"key":"10.1016\/j.jcyt.2026.102780_bib0051","unstructured":"Agencia Nacional de Vigilancia Sanitaria - ANVISA aprova registro de produto de terapia avan\u00e7ada para o cancer. 2022. Available from:https:\/\/www.gov.br\/anvisa\/pt-br\/assuntos\/noticias-anvisa\/2022\/anvisa-aprova-registro-de-produto-de-terapia-avancada-para-cancer."},{"key":"10.1016\/j.jcyt.2026.102780_bib0052","unstructured":"Brasil - Anvisa aprova mais um produto de terapia avancada para o tratamento do cancer no Brasil 2023. Available from:https:\/\/www.gov.br\/anvisa\/pt-br\/assuntos\/noticias-anvisa\/2023\/anvisa-aprova-mais-um-produto-de-terapia-avancada-para-tratamento-do-cancer-no-brasil."},{"key":"10.1016\/j.jcyt.2026.102780_bib0053","unstructured":"International Monetary Fund, Brazil [cited 2025]. Available from: https:\/\/www.imf.org\/external\/datamapper\/profile\/BRA."},{"issue":"7","key":"10.1016\/j.jcyt.2026.102780_bib0054","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1038\/s41409-024-02283-6","article-title":"Safety and efficacy of a new academic CD19-directed CAR-T cell for refractory\/relapsed non-Hodgkin lymphoma and acute lymphoblastic leukemia in Brazil","volume":"59","author":"Donadel","year":"2024","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jcyt.2026.102780_bib0055","article-title":"Clinical trials to gene therapy development and production in Brazil: a review","volume":"43","author":"Morales Saute","year":"2025","journal-title":"Lancet Reg Health Am"},{"issue":"Suppl. 1","key":"10.1016\/j.jcyt.2026.102780_bib0056","doi-asserted-by":"crossref","first-page":"4930","DOI":"10.1182\/blood-2022-170045","article-title":"Clinical validation of automated manufacture of autologous CD19 CAR-T cells for treatment of B neoplasia","volume":"140","author":"Kerbauy","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.jcyt.2026.102780_bib0057","unstructured":"Mexico - Foreign Ministry, health sector collaborate to transfer state-of-the-art India technology for cancer treatment to Mexico. Available from:https:\/\/www.gob.mx\/sre\/prensa\/foreign-ministry-health-sector-collaborate-to-transfer-state-of-the-art-indian-technology-for-cancer-treatment-to-mexico."},{"issue":"9","key":"10.1016\/j.jcyt.2026.102780_bib0058","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1016\/j.jcyt.2025.04.056","article-title":"Cellular gene therapy access in Africa: a multifactorial feasibility analysis for implementation","volume":"27","author":"Obiozor","year":"2025","journal-title":"Cytotherapy"},{"key":"10.1016\/j.jcyt.2026.102780_bib0059","unstructured":"Cipla partners with ImmunoACT to launch talicabtagene autoleucel, an anti-CD19 CAR-T cell therapy for blood cancers in Africa. 2026 [January 26, 2026]. Available from: https:\/\/www.cipla.com\/press-releases-statements\/cipla-partners-immunoact-launch-talicabtagene-autoleucel-anti-cd19-car-t."},{"key":"10.1016\/j.jcyt.2026.102780_bib0060","unstructured":"Children\u2019s Hospital Of Philadelphia launches global partnership to establish a CAR-T therapy program in Brazil [August, 2025]. Available from: https:\/\/www.chop.edu\/news\/childrens-hospital-philadelphia-launches-global-partnership-establish-car-t-therapy-program."},{"key":"10.1016\/j.jcyt.2026.102780_bib0061","unstructured":"Children\u2019s Hospital of Philadelphia. From Philly to Rio: CHOP\u2019s mission to lower CAR-T therapy cost [cited August, 2025]. Available from:https:\/\/www.research.chop.edu\/cornerstone-blog\/from-philly-to-rio-chops-mission-to-lower-car-t-therapy-cost."},{"issue":"7","key":"10.1016\/j.jcyt.2026.102780_bib0062","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1016\/j.jtct.2023.04.003","article-title":"Overcoming barriers to referral for chimeric antigen receptor T cell therapy in patients with relapsed\/refractory diffuse large B cell lymphoma","volume":"29","author":"Hoffmann","year":"2023","journal-title":"Transplant Cell Ther"},{"key":"10.1016\/j.jcyt.2026.102780_bib0063","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.1062296","article-title":"Should we adopt an automated de-centralized model of chimeric antigen receptor-T cells manufacturing for low-and middle-income countries? A real world perspective","volume":"12","author":"Ramakrishnan","year":"2022","journal-title":"Front Oncol"},{"issue":"8","key":"10.1016\/j.jcyt.2026.102780_bib0064","doi-asserted-by":"crossref","first-page":"4541","DOI":"10.1007\/s12325-021-01839-y","article-title":"Travel-related economic burden of chimeric antigen receptor T cell therapy administration by site of care","volume":"38","author":"Snyder","year":"2021","journal-title":"Adv Ther"},{"key":"10.1016\/j.jcyt.2026.102780_bib0065","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.3389\/fimmu.2020.01941","article-title":"Automated manufacture of autologous CD19 CAR-T cells for treatment of non-Hodgkin lymphoma","volume":"11","author":"Jackson","year":"2020","journal-title":"Front Immunol"},{"issue":"2","key":"10.1016\/j.jcyt.2026.102780_bib0066","article-title":"Cost-effective strategies for CAR-T cell therapy manufacturing","volume":"33","author":"Abdo","year":"2025","journal-title":"Mol Ther Oncol"},{"issue":"2","key":"10.1016\/j.jcyt.2026.102780_bib0067","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.mayocpiqo.2019.12.006","article-title":"A graduate-level interdisciplinary curriculum in CAR-T cell therapy","volume":"4","author":"Sterner","year":"2020","journal-title":"Mayo Clin Proc Innov Qual Outcomes"},{"key":"10.1016\/j.jcyt.2026.102780_bib0068","unstructured":"International Society for Cell & Gene Therapy. Early-stage professional mentoring program. 2025. Available from: ttps:\/\/www.isctglobal.org\/resources\/training-programs\/esp-mentoring-program."}],"container-title":["Cytotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1465324926007413?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1465324926007413?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T00:02:05Z","timestamp":1785974525000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1465324926007413"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":69,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S1465324926007413"],"URL":"https:\/\/doi.org\/10.1016\/j.jcyt.2026.102780","relation":{},"ISSN":["1465-3249"],"issn-type":[{"value":"1465-3249","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Overcoming challenges in the implementation of chimeric antigen receptor (CAR) T-cell therapy in resource-constrained settings: Lessons from Brazil and India","name":"articletitle","label":"Article Title"},{"value":"Cytotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcyt.2026.102780","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc. on behalf of International Society for Cell and Gene Therapy.","name":"copyright","label":"Copyright"}],"article-number":"102780"}}